"I honestly believe we're going to be a behemoth structural heart company, both aortic and mitral," cgt there are also other opportunities that the company is exploring. Below is a reply to a query I lodge some years ago - "As noted in the AGM, the company is looking at two main opportunities inaddition to progressing their TAVR development program. Both of theseopportunities fall under their ADAPT® technology. The first is the use of the technology on Dural Repair (tissue surrounding spinal cord) and second is the use of the technology on hernia (soft tissue) repair. Admedus is continuously looking at opportunities and will advise the market in due course"
Additionally they are looking at CABG so there do seem to be a lot of opportunities after DurAVR and ComASSUR are put to bed.
AVR Price at posting:
$16.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)